食管压导向PEEP滴定与经验性高PEEP-FiO2策略对中重度ARDS患者死亡及无机械通气天数的影响:随机临床试验
这项2期随机临床试验在北美14家医院纳入200例中重度ARDS患者,比较食管压导向PEEP滴定与经验性高PEEP-FiO2策略。主要复合终点(死亡和无机械通气天数)无显著差异,食管压组补救治疗需求显著更低,但其他预设次要终点无差异。
要点
- 食管压导向PEEP与经验性高PEEP-FiO2相比,主要复合终点无显著差异。
- 食管压组补救治疗需求显著更低(3.9% vs 12.2%)。
- 结果不支持在中重度ARDS中常规使用食管压导向PEEP滴定。
核心结论
- 在中重度ARDS患者中,食管压导向PEEP与经验性高PEEP-FiO2相比,死亡和无机械通气天数无显著差异。
- 这些发现不支持在ARDS中使用食管压导向PEEP滴定。
研究设计与样本
- 2期随机临床试验,在北美14家医院开展。
- 纳入200例年龄≥16岁、Pao2:Fio2≤200 mm Hg的中重度ARDS机械通气患者,随机分为食管压导向PEEP组(n=102)和经验性高PEEP-FiO2组(n=98),均接受低潮气量通气。
- 主要终点为第28天死亡和无机械通气天数的排序复合评分。
主要发现
- 主要复合终点无显著差异(食管压导向PEEP更优概率49.6% [95% CI, 41.7% to 57.5%];P = .92)。
- 28天死亡率:食管压组32.4%(33/102) vs 经验性组30.6%(30/98),风险差1.7% [95% CI, -11.1% to 14.6%];P = .88。
- 幸存者无机械通气天数中位数:22 [15-24] vs 21 [16.5-24]天,中位数差0 [95% CI, -1 to 2]天;P = .85。
- 补救治疗需求:食管压组3.9%(4/102) vs 经验性组12.2%(12/98),风险差-8.3% [95% CI, -15.8% to -0.8%];P = .04。
- 其他7个预设次要临床终点均无显著差异;不良事件包括严重气压伤,食管压组6例,经验性组5例。
临床怎么用
- 中重度ARDS患者中,食管压导向PEEP滴定未改善死亡和无机械通气天数,不应作为常规策略推广。
- 食管压导向策略可能减少补救治疗需求,但需权衡其他临床终点无差异及操作复杂性。
局限性
- 本研究为2期临床试验,样本量200例,可能不足以检测微小差异。
- 长期随访完成于2018年7月30日,但主要分析限于28天终点。
- 研究纳入中重度ARDS患者,结论外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Adjusting positive end-expiratory pressure (PEEP) to offset pleural pressure might attenuate lung injury and improve patient outcomes in acute respiratory distress syndrome (ARDS). OBJECTIVE: To determine whether PEEP titration guided by esophageal pressure (PES), an estimate of pleural pressure, was more effective than empirical high PEEP-fraction of inspired oxygen (Fio2) in moderate to severe ARDS. DESIGN, SETTING, AND PARTICIPANTS: Phase 2 randomized clinical trial conducted at 14 hospitals in North America. Two hundred mechanically ventilated patients aged 16 years and older with moderate to severe ARDS (Pao2:Fio2 ≤200 mm Hg) were enrolled between October 31, 2012, and September 14, 2017; long-term follow-up was completed July 30, 2018. INTERVENTIONS: Participants were randomized to PES-guided PEEP (n = 102) or empirical high PEEP-Fio2 (n = 98). All participants received low tidal volumes. MAIN OUTCOMES AND MEASURES: The primary outcome was a ranked composite score incorporating death and days free from mechanical ventilation among survivors through day 28. Prespecified secondary outcomes included 28-day mortality, days free from mechanical ventilation among survivors, and need for rescue therapy. RESULTS: Two hundred patients were enrolled (mean [SD] age, 56 [16] years; 46% female) and completed 28-day follow-up. The primary composite end point was not significantly different between treatment groups (probability of more favorable outcome with PES-guided PEEP: 49.6% [95% CI, 41.7% to 57.5%]; P = .92). At 28 days, 33 of 102 patients (32.4%) assigned to PES-guided PEEP and 30 of 98 patients (30.6%) assigned to empirical PEEP-Fio2 died (risk difference, 1.7% [95% CI, -11.1% to 14.6%]; P = .88). Days free from mechanical ventilation among survivors was not significantly different (median [interquartile range]: 22 [15-24] vs 21 [16.5-24] days; median difference, 0 [95% CI, -1 to 2] days; P = .85). Patients assigned to PES-guided PEEP were significantly less likely to receive rescue therapy (4/102 [3.9%] vs 12/98 [12.2%]; risk difference, -8.3% [95% CI, -15.8% to -0.8%]; P = .04). None of the 7 other prespecified secondary clinical end points were significantly different. Adverse events included gross barotrauma, which occurred in 6 patients with PES-guided PEEP and 5 patients with empirical PEEP-Fio2. CONCLUSIONS AND RELEVANCE: Among patients with moderate to severe ARDS, PES-guided PEEP, compared with empirical high PEEP-Fio2, resulted in no significant difference in death and days free from mechanical ventilation. These findings do not support PES-guided PEEP titration in ARDS. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT01681225.
引用
- Beitler JR, Sarge T, Banner-Goodspeed VM, et al. Effect of Titrating Positive End-Expiratory Pressure (PEEP) With an Esophageal Pressure-Guided Strategy vs an Empirical High PEEP-Fio2 Strategy on Death and Days Free From Mechanical Ventilation Among Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. JAMA. 2019. PMID: 30776290. doi:10.1001/jama.2019.0555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。